8th Annual USC Multidisciplinary Breast Cancer Symposium

 

8th Annual USC Multidisciplinary Breast Cancer Symposium
Avatar

USC Update on 1L Chemo Combination for Advanced TNBC: Does the Addition of Atezolizumab or Pembrolizumab Make a Difference?

By 8th Annual USC Multidisciplinary Breast Cancer Symposium FEATURING Sara A. Hurvitz
By 8th Annual USC Multidisciplinary Breast Cancer Symposium FEATURING Sara A. Hurvitz
0 views
January 28, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy

Featured Video

05:59
Lilly Medical Affairs

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy
Videos
05:35
8th Annual USC Multidisciplinary Breast Cancer Symposium

HR+HER2- High-Risk eBC: Surveying Efficacy Data of CDK4/6i in the Ad…

Feat. G. Sledge
09:19
8th Annual USC Multidisciplinary Breast Cancer Symposium

HR+/HER2- MBC: Outcomes of 1/2L CDK4/6 Inhibition

Feat. G. Sledge
09:50
8th Annual USC Multidisciplinary Breast Cancer Symposium

ER+ Early Stage BC: Which Patients Should Avoid Chemotherapy? Does C…

Feat. G. Sledge
06:22
8th Annual USC Multidisciplinary Breast Cancer Symposium

PI3K/AKT/mTOR Inhibition in Advanced BC: Is There Any Benefit With A…

Feat. G. Sledge
30:59
8th Annual USC Multidisciplinary Breast Cancer Symposium

Genetic Risk in BC: BRCA1/2 Mutations, Genetic Testing, Preventive B…

Feat. B. Arun
35:08
8th Annual USC Multidisciplinary Breast Cancer Symposium

Oncoplastic Surgery and BC: What Is Extreme Oncoplasty? When Can We …

Feat. M. Silverstein
28:38
8th Annual USC Multidisciplinary Breast Cancer Symposium

Diagnostic MRI for Newly Diagnosed BC: Factors of Occult Lesions Det…

Feat. S. Sener
39:07
8th Annual USC Multidisciplinary Breast Cancer Symposium

2021 Challenges in HER2+ BC Testing: IHC Guidelines, Biomarker Testi…

Feat. M. Press
18:27
8th Annual USC Multidisciplinary Breast Cancer Symposium

2021 Updates on HER2+ MBC: What Does the New Data on T-DXd Suggest? …

Feat. W. Gradishar
11:34
8th Annual USC Multidisciplinary Breast Cancer Symposium

2021 Updates on HER2+ MBC: Tucatinib Combo and HRQoL in Brain Mets, …

Feat. W. Gradishar
19:06
8th Annual USC Multidisciplinary Breast Cancer Symposium

USC Update on 1L Chemo Combination for Advanced TNBC: Does the Addit…

Feat. S. Hurvitz
06:31
8th Annual USC Multidisciplinary Breast Cancer Symposium

Innovations in Management of mTNBC: PARP Inhibitors

Feat. S. Hurvitz
13:11
8th Annual USC Multidisciplinary Breast Cancer Symposium

Clinical Trial Data on ADCs in TNBC: Sacituzumab Govitecan Efficacy …

Feat. S. Hurvitz